QC Kinetix Launches Groundbreaking Clinical Trial to Enhance Musculoskeletal Pain Treatment Using Regenerative Medicine
*CHARLOTTE, NC / ACCESSWIRE / February 22, 2024 /* QC Kinetix, a leader in the field of regenerative medicine, announces the launch of a new clinical trial aimed at advancing treatment and functional outcomes for patients suffering from musculoskeletal pain. This innovative study is designed to determine if patients have better outcomes with or without the use of anti-inflammatory medications when receiving Platelet Rich Plasma (PRP) injections while treating moderate osteoarthritis in the knees.
Leading the research initiative is Dr. Ken Barnes, Director of Research & Development at QC Kinetix. Dr. Barnes, a board-certified expert in sports medicine, internal medicine, and pediatrics, has an extensive background in musculoskeletal sports injuries, regenerative medicine, clinical research, and orthobiologics. His academic contributions include serving as a faculty member at multiple prestigious institutions and as a team physician for renowned sports teams, including MLB, AHL, NCAA Division 1, and multiple high schools. Dr. Barnes brings a wealth of knowledge and experience to this trial, strengthened by his commitment to evidence-based medicine.
"At QC Kinetix, our priority is continual improvement and innovation, with a strong emphasis on patient safety," said Dr. Barnes. "This trial represents our commitment to rigorously testing our protocols to ensure the best possible outcomes for our patients. We are excited to explore how PRP injections, coupled with or without the use of anti-inflammatory medications, can enhance the healing process, improve functionality, and decrease pain for those suffering from musculoskeletal conditions."
The clinical trial will enroll participants experiencing unilateral knee joint pain, with a moderate level of osteoarthritis, who are at least 50 years old. Eligible participants will undergo a thorough screening process, including an initial visit, X-ray examination, and a series of questionnaires. They will then receive three PRP injections over a span of three months, Medications for six months, and follow-up visits to monitor their progress over a twelve-month enrollment period. The study aims to quantify improvements in pain and function using standardized, validated questionnaires and assess the benefit of using or discontinuing anti-inflammatory medications during regenerative treatment.
In this double-blinded randomized controlled clinical trial, participants will be randomly assigned to one of three groups to receive either acetaminophen, ibuprofen, or a placebo, without knowing which group they belong to. This blind study method will help determine the true effects of PRP therapy in conjunction with standard pain management approaches.
The trial will be conducted in selected QC Kinetix clinics across Greenville, South Carolina; Charleston/Mount Pleasant, South Carolina; and Charlotte, North Carolina. With an aim to recruit 100 participants for each group, the study is expected to span from three to five years, depending on recruitment rates. The Institutional Review Board (IRB) will oversee the study to ensure patient safety and integrity throughout the process.
"This study is crucial not only for advancing our understanding of regenerative medicine but also for potentially redefining how we approach the treatment of musculoskeletal pain," said Dr. Barnes. "Our goal is to contribute significantly to the literature on regenerative medicine and ultimately improve patient care and outcomes."
QC Kinetix is dedicated to leading the way in regenerative medicine by conducting rigorous clinical trials and research. Results from this study will inform future treatment protocols and underscore the company's commitment to providing innovative, evidence- based, patient-centered care.
For more information on the clinical trial and how to participate, please visit www.qckinetix.com.
*MEDIA CONTACT:*
Jennifer Williams
jwilliams@919marketing.com | Ph: 919.459.3592
###
*About QC Kinetix*
QC Kinetix is a Charlotte, North Carolina-based franchise company leading the way in helping people maintain an active lifestyle using comprehensive regenerative medicine treatments to address musculoskeletal and joint pain. QC Kinetix uses the body's own healing properties through state-of-the-art natural biologic treatments as alternatives to invasive surgery and addictive pain medications. The healthcare franchise currently operates in more than 50 cities with rapid growth underway throughout the U.S. QC Kinetix clinics are dedicated to maximizing the body's ability to help heal and repair itself from the inside out for vastly improved function and overall quality of life. For more information, visit www.qckinetix.com
*SOURCE: *QC Kinetix
View the original press release on accesswire.com